Advanced Search

 

Study ID Status Title Patient Level Data
NUC20917 Completed A double-blind, active-controlled, randomized 52-week extended follow-on study to investigate the long-term efficacy and safety of adefovir dipivoxil 10mg and lamivudine 100mg treatment for subjects with hepatitis B who have completed the previous Phase II protocol NUC20904
NUC20921 Completed Open-label compassionate access programme to provide adefovir dipivoxil and lamivudine to patients with Chronic Hepatitis B infection who are participating in or have completed, as appropriate, one of the following GlaxoSmithKline or Gilead Sciences Inc. clinical trials: NUC20917, NUC20912, NUCB4006
NUC30902 Completed A multicenter, prospective, descriptive study to compare the efficacy of lamivudine alone versus lamivudine plus anti-HB hyperimmune gammaglobulin in the prevention of hepatitis B virus reinfection after liver transplant.
NUC30903 Completed A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of 52 Weeks Lamivudine Treatment at a Dose of 3 mg/kg in Paediatric Subjects with Chronic Hepatitis B
NUC30907 Completed A randomized, double-blind, placebo-controlled study of the treatment of HBsAg positive patients after stable renal transplantation with lamivudine
NUC30910 Completed Lamivudine for Prevention of HBV Reactivation in HBsAg Seropositive Patients undergoing Cytotoxic Chemotherapy
NUC30914 Completed A multicentre, randomised, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of recombinant HBV vaccine and hepatitis B immunoglobulin (HBIg) plus lamivudine versus recombinant HBV vaccine and HBlg plus placebo for the prevention of mother-to-child transmission of HBV. Study Listed on ClinicalStudyDataRequest.com
NUC30919 Completed A double blind randomised multicentre study of lamivudine added to the current treatment in the therapy of chronic hepatitis B in HBV-DNA/anti-HBe positive Subjects.
NUC30925 Completed An open-label, Phase-IV study to demonstrate the efficacy and safety of locally manufactured (Suzhou, China) Lamivudine tablets (100mg) in Chinese patients with chronic hepatitis B (CHB)
NUC30926 Completed An Extended, Stratified Follow-on Study In Paediatric Subjects With Chronic Hepatitis B Who Have Completed Previous Lamivudine Studies Study Listed on ClinicalStudyDataRequest.com
NUC30928 Completed A multicentre, single-arm, non-randomised trial to evaluate the efficacy and safety of lamivudine 100mg once a day in patients with chronic hepatitis B virus infection.
NUC30931 Completed Multicentre, open study to determine the effect of Lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection
NUC30933 Completed A Study of the Safety and Efficacy of Lamivudine 100 mg OD in Egyptian Patients with Chronic Replicating Hepatitis B Virus (CHB).
NUC30935 Completed A Randomised, Multicenter, Placebo-Controlled Study to Assess the Efficacy and Optimal Duration of Lamivudine Treatment in Patients with Pre-core Mutant HBV Study Listed on ClinicalStudyDataRequest.com
NUC30937 Completed An open label one year study of lamivudine in patients with chronic hepatitis.
NUC30938 Completed A randomised trial of lamivudine plus interferon versus lamivudine for the treatment of HBeAg positive chronic hepatitis B virus (HBV)
NUC30944 Completed A study of the safety and efficacy of Lamivudine 100 mg OD in patients with HBeAg negative (presumed pre-core mutant) chronic hepatitis B virus infection.
nuc30957 Completed Phase III clinical study of GG714 (Lamivudine) Tablet - A double-blind, placebo-controlled study to investigate the efficacy and safety of Lamivudine 100 mg o.d. vs placebo in subjects with compensated cirrhosis B -
NUC30958 Completed A Phase III Clinical Study of GG714 (Lamivudine) Tablet-A study of extended GG714 treatment for subjects with hepatitis B-related Cirrhosis (long-term study)
NUC40019 Completed An open study to determine the safety and efficacy of lamivudine in subjects with chronic hepatitis B
NUC40021 Completed A Stratified, Partially Randomised (Stratum B only), Double Blind, Multicentre Trial of Lamivudine and Adefovir Dipivoxil Treatment for Patients with Chronic Hepatitis B Who Have Shown Disease Progression by Reaching a Clinical Endpoint
NUC40031 Completed Open study to determine the effect of Lamivudine on liver histology and DNA HBV suppression in patients after seroconversion in HBeAg and with HBsAg present
NUC40032 Completed Pre-emptive Lamivudine and Chemotherapy-induced Hepatitis B Virus Reactivation in Patients with Hematologic Malignancies
NUC40036 Completed An open-label, Phase IV study to examine whether the duration of lamivudine treatment following HBeAg seroconversion affects the durability of the HBeAg seroconversion response in Asian patients.
NUC40040 Completed An Extended, Observational Study in Pediatric Patients with Chronic Hepatitis B Who Have Previously Received Long-Term Lamivudine Treatment Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.